Olefir Yu V, Yavorskii A N, Butnaru D V, Shatalova O V, Gorbatenko V S, Gerasimenko A S
I.M. Sechenov First MSMU, Moscow, Russia.
Scientific Centre for Expert Evaluation of Medicinal Products, Moscow, Russia.
Urologiia. 2017 Dec(6):112-119.
Most patients with idiopathic hypercalciuria and calcium nephrolithiasis have a family history of the disease. Idiopathic hypercalciuria is a metabolic abnormality with various causes and developmental pathways. The systematic review describes specific mutations associated with idiopathic hypercalciuria and nephrolithiasis. Detection of these mutations may provide a better understanding of the pathogenesis of this heterogeneous disease and personalize patient management depending on the detected polymorphisms. A promising treatment option for a mutation in the vitamin D receptor gene is thiazide diuretics in combination with bisphosphonates. Among bisphosphonates, the drug of choice which has been most strongly supported by research evidence is alendronate.
大多数特发性高钙尿症和钙肾结石患者有该疾病的家族史。特发性高钙尿症是一种具有多种病因和发展途径的代谢异常。该系统评价描述了与特发性高钙尿症和肾结石相关的特定突变。检测这些突变可能有助于更好地理解这种异质性疾病的发病机制,并根据检测到的多态性对患者进行个性化管理。维生素D受体基因突变的一种有前景的治疗选择是噻嗪类利尿剂联合双膦酸盐。在双膦酸盐中,研究证据最有力支持的首选药物是阿仑膦酸钠。